Urinary Prostate Cancer 3 Test: Toward the Age of Reason?

Urology

Volumn 75, Issue 2, 2010, Pages 447-453

  Vlaeminck Guillem, Virginie ^a,b   Ruffion, Alain ^a,b   André, Jean ^a,b   Devonec, Marian ^a,b   Paparel, Philippe ^a,b  

^a CENTRE HOSPITALIER LYON SUD   (France)

^b UNIVERSITÉ LYON 1   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACCURACY; CANCER DIAGNOSIS; CANCER TEST; GENE EXPRESSION; HUMAN; PCA3 TUMOR GENE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE BIOPSY; PROSTATE CANCER; REVIEW; SENSITIVITY ANALYSIS; TUMOR GENE; URINALYSIS;

ANTIGENS, NEOPLASM; HUMANS; MALE; PROSTATIC NEOPLASMS; REPRODUCIBILITY OF RESULTS; RNA;

EID: 75349113624     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2009.03.046     Document Type: Review

References (28)

1. Schröder F.H., Carter H.B., Wolters T., et al. Early detection of prostate cancer in 2007. Part 1: PSA and PSA kinetics. Eur Urol 53 (2008) 468-477
2. Hessels D., Klein Gunnewiek J.M., van Oort I., et al. DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol 44 (2003) 8-15
3. Bussemakers M.J., van Bokhoven A., Verhaegh G.W., et al. DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res 59 (1999) 5975-5979
4. Mattick J.S., and Makunin I.V. Non-coding RNA. Hum Mol Genet 15 (2006) R17-R29
5. Schalken J.A., Hessels D., and Verhaegh G. New targets for therapy in prostate cancer: differential display code 3 (DD3(PCA3)), a highly prostate cancer-specific gene. Urology 62 (2003) 34-43
6. de Kok J.B., Verhaegh G.W., Roelofs R.W., et al. DD3(PCA3), a very sensitive and specific marker to detect prostate tumors. Cancer Res 62 (2002) 2695-2698
7. Popa I., Fradet Y., Beaudry G., et al. Identification of PCA3 (DD3) in prostatic carcinoma by in situ hybridization. Mod Pathol 20 (2007) 1121-1127
8. Bialkowska-Hobrzanska H., Driman D.K., Fletcher R., et al. Expression of human telomerase reverse transcriptase, Survivin, DD3 and PCGEM1 messenger RNA in archival prostate carcinoma tissue. Can J Urol 13 (2006) 2967-2974
9. Landers K.A., Burger M.J., Tebay M.A., et al. Use of multiple biomarkers for a molecular diagnosis of prostate cancer. Int J Cancer 114 (2005) 950-956
10. Balcerczak E., Mirowski M., Sasor A., et al. Expression of p65, DD3 and c-erbB2 genes in prostate cancer. Neoplasma 50 (2003) 97-101
11. van Bokhoven A., Varella-Garcia M., Korch C., et al. Molecular characterization of human prostate carcinoma cell lines. Prostate 57 (2003) 205-225
12. van Gils M.P., Cornel E.B., Hessels D., et al. Molecular PCA3 diagnostics on prostatic fluid. Prostate 67 (2007) 881-887
13. Tinzl M., Marberger M., Horvath S., et al. DD3PCA3 RNA analysis in urine-a new perspective for detecting prostate cancer. Eur Urol 46 (2004) 182-186
14. Fradet Y., Saad F., Aprikian A., et al. uPM3, a new molecular urine test for the detection of prostate cancer. Urology 64 (2004) 311-315
15. Groskopf J., Aubin S.M., Deras I.L., et al. APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer. Clin Chem 52 (2006) 1089-1095
16. van Gils M.P., Hessels D., van Hooij O., et al. The time-resolved fluorescence-based PCA3 test on urinary sediments after digital rectal examination; a Dutch multicenter validation of the diagnostic performance. Clin Cancer Res 13 (2007) 939-943
17. Haese A., de la Taille A., van Poppel H., et al. Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy. Eur Urol 54 (2008) 1081-1088
18. Marks L.S., Fradet Y., Deras I.L., et al. PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy. Urology 69 (2007) 532-535
19. Nakanishi H., Groskopf J., Fritsche H.A., et al. PCA3 molecular urine assay correlates with prostate cancer tumor volume: implication in selecting candidates for active surveillance. J Urol 179 (2008) 1804-1809
20. Shappell S.B., Fulmer J., Arquello D., et al. PCA3 urine mRNA testing for prostate carcinoma: patterns of use by community urologists and assay performance in reference laboratory setting. Urology 73 (2009) 363-368
21. Deras I.L., Aubin S.M., Blase A., et al. PCA3: a molecular urine assay for predicting prostate biopsy outcome. J Urol 179 (2008) 1587-1592
22. Sokoll L.J., Ellis W., Lange P., et al. A multicenter evaluation of the PCA3 molecular urine test: pre-analytical effects, analytical performance, and diagnostic accuracy. Clinica Chim Acta 389 (2008) 1-6
23. Magklara A., Scolaris A., Stephan C., et al. Decreased concentrations of prostate-specific antigen and human glandular kallikrein 2 in malignant versus nonmalignant prostatic tissue. Urology 56 (2000) 527-532
24. Bostwick D.G., Gould V.E., Qian J., et al. Prostate cancer detected by uPM3: radical prostatectomy findings. Mod Pathol 19 (2006) 630-633
25. van Gils M.P., Hessels D., Hulsbergen-van de Kaa C.A., et al. Detailed analysis of histopathological parameters in radical prostatectomy specimens and PCA3 urine test results. Prostate 68 (2008) 1215-1222
26. Whitman E.J., Groskopf J., Ali A., et al. PCA3 score before radical prostatectomy predicts extracapsular extension and tumor volume. J Urol 180 (2008) 1975-1978
27. Hessels D., Smit F.P., Verhaegh G.W., et al. Detection of TMPRSS2-ERG fusion transcripts and prostate cancer antigen 3 in urinary sediments may improve diagnosis of prostate cancer. Clin Cancer Res 13 (2007) 5103-5108
28. Laxman B., Morris D.S., Yu J., et al. A first-generation multiplex biomarker analysis of urine for the early detection of prostate cancer. Cancer Res 68 (2008) 645-649